Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. [electronic resource]
Producer: 20090115Description: 465-72 p. digitalISSN:- 1097-0215
- Animals
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Cell Line, Tumor
- Cyclin-Dependent Kinase Inhibitor p27 -- metabolism
- Cyclin-Dependent Kinases -- metabolism
- Doxorubicin -- administration & dosage
- Drug Synergism
- Female
- Humans
- Mammary Neoplasms, Animal -- drug therapy
- Mice
- Mice, Nude
- Neoplasm Transplantation
- Protein Kinase Inhibitors -- administration & dosage
- Purines -- administration & dosage
- Roscovitine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.